RVTY — Revvity, Inc.

Sentiment has been driven by a re-rating rather than by reported earnings: as of 2026-09-13 the stock was up ~45% in six months even as GAAP EPS stayed low, with investors rewarding the 'adjusted EPS + free cash flow + AI innovation' narrative. Q2 2026 delivered an adjusted EPS beat ($1.41 vs ~$1.21) and a guidance raise, prompting UBS ($140 target) and KeyBanc ($165) to lift targets, while JPMorgan and Bernstein stayed sidelined flagging a rich forward multiple. The consensus Buy rating is lukewarm — 15 buys vs 14 holds across 29 analysts — and the average target (~$124–$136) sits almost exactly on the current price, implying the Street sees little obvious upside. A -4.5% week as of 2026-09-13 suggests some profit-taking after the run.

Revenue has been range-bound for three years — quarterly prints of $650M–$772M with a clear Q4-strong/Q1-weak seasonal pattern — and growth is modest but stable: YoY of +2.3% (Q1'25), +4.1% (Q2'25), +2.2% (Q3'25), +5.9% (Q4'25), +7.0% (Q1'26), then +1.3% (Q2'26). The Q2'26 slowdown is largely divestiture drag — management cites 3% organic (4% pro forma) — not demand deterioration. Gross margin is quietly improving (Q2'26 gross profit 57.1% of revenue vs 54.5% in Q2'25 and 56.3% in Q2'24), but GAAP operating margin has compressed materially, from ~14.7% in Q2'24 and 18.1% in Q4'24 to ~12.2% in Q2'26 and 14.5% in Q4'25 — a real opex/mix headwind. GAAP EPS is low and volatile ($0.36–$0.87) and roughly a third of adjusted EPS. The cleanest positive is free cash flow, which inflected sharply: Q2'26 FCF of $180.9M versus $115.5M in Q2'25 (+57%), lifting TTM FCF to ~$559M. Verdict: a slow, steady recovery with improving cash generation, not a sharp inflection — the recent stock strength is more re-rating than business acceleration.

Reporting-based multiples look expensive; adjusted/cash multiples look merely full. As of 2026-09-13 the TTM P/E was 59.2x on GAAP EPS of $2.13 versus the stock's 5-year average P/E of 37.2x (the 'rich' flag), but GAAP EPS is heavily burdened by intangible amortization. On the FY2026 adjusted EPS guide midpoint of $5.35, the forward P/E is ~23.2x — roughly in line with life-sciences tools peers and consistent with 4–5% organic growth. P/S of 4.76x is actually slightly below the 5-year average of 5.04x, and P/B is a modest 1.92x. Against ~$559M TTM free cash flow, the stock yields ~4.0% FCF. Net: fairly valued to modestly rich — not a bargain, not egregious.

This is a 'priced-for-the-turnaround' setup. The stock re-rated ~45% over six months while GAAP earnings actually declined — the market is underwriting adjusted EPS, cash flow, and the AI/innovation narrative, not reported profit. That means the multiple expanded ahead of confirmed acceleration: organic growth is still only ~3–4% and GAAP operating margin compressed to ~12%. If organic growth accelerates toward 5–6% and margins recover, the stock can grow into its ~23x forward multiple; if growth stalls or guidance disappoints, there is little valuation cushion and multiple compression is the risk. Watch the GAAP-to-adjusted EPS gap — investors are paying for $1.41 in adjusted Q2'26 EPS, not the $0.47 reported.

As of 2026-09-13, RSI(14) was 53.2 — neutral, with no overbought/oversold signal. The $124.31 price sat essentially on its 20-day SMA (-0.19%), +5.93% above the 50-day and +20.74% above the 200-day — a clean uptrend that has recently paused (down 4.54% over the prior week, +5.45% over one month, +24.73% over three, +45.27% over six). The 52-week range is $81.22–$133.00, so the stock is near the top of its range (~93% of the high). Implication: momentum is intact but the low-risk entry has passed; chasing near a 52-week high after a 45% run offers poor risk/reward, while a pullback toward $115–120 (near the 50-day) would be a better spot to add.

• Biotech/pharma R&D funding — the single biggest demand driver; early-stage venture funding is stabilizing selectively but enterprise pharma spend remains cautious, directly gating instrument and consumable orders.
• Interest-rate trajectory — expected monetary easing supports multiple expansion for long-duration healthcare/tech names, but RVTY's full multiple leaves it sensitive to any hawkish surprise.
• China/Asia pricing and regulation — ongoing pressure and geopolitical friction are driving Revvity to prune lower-margin regional assets (China Immunodiagnostics divestiture).
• Tariffs and global trade policy — instrument and consumable supply chains and cross-border sales are exposed to tariff/trade friction.
• Healthcare sector rotation — defensive medtech/life-sciences tools have benefited from rotation into healthcare, a tailwind for the multiple that can reverse.

• Q3 2026 earnings (expected late October 2026) — the next hard read on whether organic growth is accelerating toward 5%+ and whether GAAP margins stabilize.
• Portfolio moves — completion/execution of the pending China Immunodiagnostics divestiture and the Sept 9, 2026 Human Cell Design acquisition; success would clean up the growth/margin mix.
• New product ramp — Signals AI (Anthropic-integrated), SuperFlex preeclampsia screening, and the high-throughput T-SPOT.TB platform are incremental revenue drivers.
• Biotech funding recovery — a sustained rebound would lift instrument/consumable demand and support guidance upgrades.
• Fall investor conferences (Morgan Stanley, Baird healthcare) — potential mid-quarter updates and target revisions.

• Valuation risk — ~23x forward adjusted EPS on only ~4% organic growth leaves little cushion; a stall would likely compress the multiple.
• Earnings-quality gap — GAAP operating margin compressed from ~15–18% (2024) to ~10–14% (2025–26), and GAAP EPS (~$0.47) is roughly a third of adjusted (~$1.41); heavy reliance on adjustments.
• Geographic/divestiture execution — China exposure, pricing pressure, and risk that divestitures remove revenue faster than costs.
• End-market demand — a relapse in biotech funding or continued cautious enterprise pharma spend would pressure growth.
• Leverage/M&A — $2.63B long-term debt against a $13.9B market cap; debt-funded tuck-ins add integration risk (D/E 0.46 is manageable but not trivial).

Revvity is a solid, genuinely cash-generative life-sciences tools franchise (TTM FCF ~$559M, ~4% FCF yield, strong balance sheet) that has re-rated sharply on a turnaround and AI/innovation narrative. But the underlying fundamentals are only 'fair' — 3–4% organic growth, GAAP operating margin compressed to ~12%, ROIC of 2.8% — and the stock now trades near the top of its 52-week range at ~23x forward adjusted EPS, with the Street's average target sitting basically on the current price. This is a fairly valued quality name, not a bargain: attractive to own on a pullback toward $115–120, but not compelling to chase at $124.

Applied a ~25x justified forward multiple (in line with quality life-sciences tools peers such as Thermo/Danaher/Agilent and appropriate for ~4–5% organic growth, high recurring consumable revenue, and strong FCF) to next-12-month adjusted EPS of ~$5.35 (FY2026 guidance midpoint, also the FY2027 consensus). Cross-checked against a ~4.0% FCF yield on ~$559M TTM free cash flow, which implies a market cap of ~$14B (~$125) and ~$15B (~$135) at a 3.7% yield — centering the fair value near $134.